MEDIZINISCHE UNIVERSITAT INNSBRUCK Patent applications |
Patent application number | Title | Published |
20110239311 | Agonists of NR2F6 For Immunosupression - The present invention relates to agonists/activators of NR2F6 (nuclear orphan receptor receptor Ear2) for the treatment of a disease related to an augmented immune response. Furthermore, pharmaceutical compositions comprising said agonists/activators of NR2F6 and a pharmaceutical carrier are comprised. In a further aspect, the present invention provides for a method for identifying immunosuppressants comprising contacting a cell, tissue or a non-human animal comprising a reporter construct for NR2F6-activation with a candidate molecule, measuring the reporter signal and selecting a candidate molecule which alters the reporter signal. Furthermore, the present invention relates to non-human transgenic animals or cells or tissue derived therefrom useful in the provided methods for identifying immunosuppressants. In yet another aspect, the present invention relates to ligand-mediated reporter gene expression constructs, ligand displacement constructs, fluorescent cellular sensor fusion mutant constructs, and ligand-induced homo- and/or heterodimer constructs useful in the provided methods for identifying immunosuppressants. | 09-29-2011 |
20110236427 | Antagonists of NR2F6 For Augmenting The Immune Response - The present invention relates to antagonists/inhibitors of NR2F6 (nuclear orphan receptor receptor Ear2) for the treatment of a disease related to an insufficient immune response. Furthermore, pharmaceutical compositions comprising said antagonists/inhibitors of NR2F6 and a pharmaceutical carrier are comprised. In a further aspect, the present invention provides for a method for identifying immunoaugmenting agents comprising contacting a cell, tissue or a non-human animal comprising a reporter construct for NR2F6-inhibition with a candidate molecule, measuring the reporter signal and selecting a candidate molecule which alters the reporter signal. Furthermore, the present invention relates to the non-human transgenic animals or cells or tissue derived therefrom useful in the provided methods for identifying immunoaugmenting agents. In yet another aspect, the present invention relates to ligand-mediated reporter gene expression constructs, ligand displacement constructs, fluorescent cellular sensor fusion mutant constructs and ligand-induced homo- and/or heterodimer constructs useful in the provided methods for identifying immunoaugmenting agents. | 09-29-2011 |
20110159018 | COMPLEMENT FACTOR H-DERIVED SHORT CONSENSUS REPEAT-ANTIBODY CONSTRUCTS - The present invention relates to a complement activating construct comprising a complement factor H-derived short consensus repeat (fH-derived SCR) and a binding molecule which specifically recognizes a pathogen. More specifically, the fH-derived SCR is selected from the group consisting of SCR7, SCR9, SCR13, SCR18-20 and artificial SCR (aSCR). Furthermore, an in vivo method for screening complement-based approaches for the treatment of the prevention, treatment or amelioration of an infection with a pathogen or a pathological condition associated with an infection with a pathogen is described. | 06-30-2011 |
20100260808 | Method for Increasing Immunoreactivity - The invention relates to an in vitro or ex vivo method for increasing the immunoreactivity of cells of the immune system, which were contacted with an antigen, said method comprising the reduction or inhibition of the Cbl-b function of said cells, thereby increasing the immunoreactivity of the cells towards the antigen. | 10-14-2010 |
20100143951 | NOVEL MARKERS FOR CHRONIC KIDNEY DISEASE - The present invention relates to a method for the determination or prediction of the progression of chronic kidney disease in a subject suspected to suffer from chronic kidney disease, said method comprising the step of determining the expression levels of at least one marker selected from (a) FGF23; and (b) adiponectin in a biological sample. Furthermore, the present invention relates to a use of a specific detection molecule for FGF23 or use of a specific detection molecule for adiponectin for the preparation of a diagnostic composition for the detection of chronic kidney disease or the progression of chronic kidney diseases in a subject suspected to suffer from said disease. In particular, the present invention also provides for use of FGF23 and/or of adiponectin as an in vitro marker for the presence, absence or progression of a chronic kidney disease and kits comprising a specific detection molecule for FGF23 or a specific detection molecule for adiponectin for use in the method of the present invention. | 06-10-2010 |